Ultrasound to Drive Cancer Drug Therapies

Ultrasound waves drive drug therapies to cancer cells and helps minimize associated toxicity.

While ultrasound has been for decades to image organs, check blood flow, and monitor the development of fetuses, new study tests the use of these pulsed sound waves to direct and focus cancer drug therapies. The study is being conducted by a Norwegian biotech company called Phoenix Solutions AS in collaboration with the Translational Genomics Research Institute (TGen), a Phoenix, Arizona-based biomedical research facility.

In laboratory tests, TGen will help analyze the effectiveness of a technology called Acoustic Cluster Therapy (ACT), a unique approach to targeting cancer cells by concentrating the delivery of chemotherapies, making them more effective and potentially reducing their toxicity.

Cell Phone Radiation and Cancer - Unveiling the Link
Scared after hearing all the harmful effects of cell phone use? Read on to find more about what cell phone radiation actually does and how you can cut down on the exposure.

‘Ultrasound based approach may help target cancer cells by concentrating the delivery of chemotherapies, making them more effective and potentially reducing their toxicity.’

Humanscan Co. Ltd., a South Korean manufacture of ultrasound diagnostic imaging, is developing clinically applicable hardware optimized for ACT, which TGen will then validate.

Phoenix Solutions is using funding from Innovation Norway to conduct this research in advance of pancreatic cancer clinical trials planned later this year.

"We are very pleased to receive this grant, which will enable us to develop and validate an optimal ultrasound platform for clinical use of ACT. In their respective fields, Humanscan and TGen both represent the cutting edge of science, and we are confident this will contribute to the clinical success of our program," said Dr. Per Sontum, CEO of Phoenix Solutions.

Screening for Breast Cancer with Clinical Breast Examination
Clinical breast examination is a simple and inexpensive method of detecting breast cancer especially in women who do not have access to mammography.

TGen is a world leader in the development of novel therapeutics for the treatment of pancreatic cancer. The TGen team led the clinical development of one of the current standard-of-care regimens for this disease -- nab-paclitaxel plus gemcitabine. TGen currently is involved in 13 pancreatic cancer clinical programs.

"We are pleased that this research program has become a reality, and look forward to working with ACT. The concept represents a novel approach to targeted drug delivery and looks very promising," said Dr. Haiyong Han, a Professor in TGen's Molecular Medicine Division and head of the Basic Research Unit in TGen's Pancreatic Cancer Program.